A Lifetime Dedicated to Drug Development and Patient Care

My inspiration began early and came from two powerful influences.

The first was my family. My father was a physician and surgeon, and my mother was a nurse. Beginning at the age of five, I accompanied my father on house calls and hospital visits. Watching him care for patients, and seeing how the medicines he prescribed could help restore their health, left a lasting impression on me.

The second influence was the emergence of television in the 1950s. I was captivated by biographical films about pioneers such as Louis Pasteur, Marie Curie, Edward Jenner and other scientific innovators. Their stories sparked my imagination and fueled my fascination with discovery and healing. Inspired by what I saw, I even conducted my own experiments in our basement, though not always with successful results.

These experiences shaped my sense of purpose from a very young age. I knew I wanted to pursue a path that combined science, innovation and medicine. I was eager to develop the skills that would one day give me the opportunity to design medicines and advance new approaches that could improve patients' lives.

Protecting the Integrity of Clinical Trials

The realm of clinical trials, as far back as I can remember, has suffered from a failure to respect the impact and rationale of clinical trial protocols on study outcomes. Today, especially, clinical trial failure is often the result of excessive political and extracurricular influence.

In my view, all trials, particularly Phase 3 trials, are built around a focus on success derived from sound science, the statistics supporting that science and the clinical efficacy that emerges from the marriage of these factors. Together, they define a study design centered on patient benefit.

When studies allow deviations or intra-study medical practices to irrationally or politically stray from that objectively defined structure, the outcome of the trial is put at risk. I believe such conduct can produce an untrue answer regarding the utility of a drug. In other words, a bad drug can appear good or a good drug can appear bad. Neither result accomplishes anything; both do harm.

I believe improved clinical trial vigilance and greater respect for the rigor of trial design are needed to ensure the reliability of clinical trial outcomes.

Building a highly integrated team with deep expertise across medicine, science, drug law and operations is, in my view, the best approach to this challenge. The importance of such a team cannot be overstated.

Success begins with operational integration at the idea stage. Early and critical assessment is essential. However, such an approach can only succeed in an environment where ideas and concerns can be freely expressed, and where serious issues are not overshadowed by extracurricular influences.

While this may not always reflect the real world, striving toward that ideal remains necessary if we are to successfully balance scientific innovation, patient safety and evolving regulatory requirements.

Using AI to Find Better Answers

I say this without any intention of patronizing the current trend, but AI can be a remarkable aid throughout the drug development process. We have used it, and continue to use it, extensively.

To use AI effectively, I believe it is important to recognize that AI is not the tool. It is an amorphous collection of 1s and 0s. In my view, the team is the tool. AI only works when a team is skilled enough to develop sophisticated interrogative constructs that force it to behave objectively.

We have had great success with our approaches to both preclinical and clinical AI assessments. These methods have helped us avoid safety issues, improve drug administration strategies, establish dosing parameters, design efficacy standards and manage changes in trial design. The result is significantly reduced development costs and timelines.

Most importantly, patients are safer, and clinical trials are better designed to deliver a true answer.

Skills Matter, Mindset Matters More

Regardless of whether someone is a PhD, MD or another professional involved in drug development, I believe understanding clinical trial design is critical. Equally important is understanding how to integrate diverse skills into the drug development process.

In my experience, medical practice, statistics, chemistry, disease idiosyncrasies, disease natural history and regulatory affairs are all essential areas of expertise. Creating an environment where critical thinking and open discussion can flourish will lead to meaningful outcomes with a lower probability of error.

Above all, I believe a patient-centered mindset should drive the team environment. That is the outcome we are all working toward. When patients win, everyone wins.